A novel machine learning-driven surface-enhanced Raman spectroscopy (SERS) platform showcased remarkable diagnostic prowess in identifying peritoneal metastasis in gastric cancer patients. The PCA-LDA model achieved an accuracy of 95.7%, sensitivity of 87.0%, and specificity of 95.5%, all significantly outperforming traditional methods like exfoliative cytology and CT scans. This innovative approach promises to streamline and enhance […]
Category: Cytoreductive Surgery & Peritoneum
Multimodal therapies enhance survival in advanced cancer patients
Researchers found that cytoreductive surgery combined with multimodal therapies significantly improved overall survival and progression-free survival in patients with advanced ovarian, colorectal, and gastric cancers. Analyzing data from 13 studies involving nearly 4,000 patients, the experimental group showed a 14% decrease in mortality risk and enhanced survival rates, although associated with a higher risk of […]
Higher compliance with ERAS pathways improves postoperative outcomes
Enhanced recovery pathways significantly reduced postoperative morbidity and LOS in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Among 150 patients studied, average compliance reached 77.6%, showing a notable negative correlation with postoperative complications and delays in return to intended oncological therapy. Specifically, patients with compliance below 71.6% faced increased morbidity. These findings support the efficacy of […]
Advances in treating peritoneal oligometastasis in gastric cancer
Peritoneal metastasis from gastric cancer significantly impacts prognosis, but advancements in diagnostic and therapeutic strategies are transforming patient outcomes. A peritoneal cancer index (PCI) threshold of ≤6 identifies patients with oligometastasis who may benefit from aggressive therapies. Cytoreductive surgery coupled with hyperthermic intraperitoneal chemotherapy remains essential for curative intent. Emerging techniques like normothermic and pressurized […]
New guidelines prioritize systemic therapy for colorectal cancer with peritoneal metastases
Consensus guidelines for managing colorectal cancer with peritoneal metastases emphasize early referral to specialized centers. A national panel achieved over 90% consensus on clinical pathways, favoring systemic therapy over upfront surgery in synchronous cases. In metachronous cases, risk stratification was updated. Although the overall evidence remains low, the guidelines represent significant progress in addressing optimal […]
Cytoreductive surgery improves survival in metastatic colorectal cancer.
National trends indicate that the utilization of cytoreductive surgery (CRS) for metastatic colorectal cancer (mCRC) increased from 33.1% in 2004 to 38.3% in 2015. In a cohort of 88,593 patients, those undergoing CRS exhibited significantly better overall survival (OS) compared to non-surgical patients, with median OS at 34.4 months, versus 13.2 months for no surgery. […]
Mass-based drug screening shows promise for personalized chemotherapy
A phase II clinical trial demonstrates the feasibility of mass-based response testing (MRT) in tailoring intraperitoneal chemotherapy for patients with unresectable appendiceal or colorectal peritoneal metastases. MRT assessed tumor susceptibility to various HIPEC drug regimens, offering a personalized approach to treatment. The study aims to improve outcomes by personalizing regimens based on patient-specific sensitivities, thereby […]
AI Framework Enhances Predictive Accuracy for Colorectal Cancer Surgery
A novel deep-learning model, known as DEAF, accurately predicts the completeness of cytoreductive surgery (CRS) in colorectal cancer patients with peritoneal metastasis. Achieving an area under the curve (AUC) of 0.9 in the internal validation cohort, and higher AUC values in three external cohorts, the model aids in selecting suitable patients for surgery and anticipating […]
Elevated preoperative tumor markers affect survival in cancer patients
Elevated preoperative levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 125 (CA125) in colorectal cancer patients with peritoneal metastases significantly influence overall survival. In a study of 204 patients, the presence of high CA19-9 and CA125 was linked to poorer outcomes, with hazard ratios of 2.7 and 2.2, respectively. Histopathological features […]
Advances in managing gastric cancer with peritoneal metastasis
Recent insights into gastric cancer with peritoneal metastasis (gcpm) reveal dismal outcomes, underscoring the need for improved management strategies. A growing body of clinical trials investigates the efficacy of cytoreductive surgery (crs) combined with hyperthermic intraperitoneal chemotherapy (hipec), recognized in new national guidelines. Enhanced understanding of gcpm’s mechanisms and novel therapeutic targets could lead to […]